Aljnadi IM, Bahls B, Duarte N, Victor BL, Mendes E, Camões SP, Miranda JP, Maçôas E, Paulo A. Exploiting the 5-Amino-11H-Indolo[3,2-c]isoquinoline Core to Achieve Better G-Quadruplex Ligands for Cancer Therapy.
ChemMedChem 2025:e2401019. [PMID:
40135720 DOI:
10.1002/cmdc.202401019]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2024] [Revised: 03/25/2025] [Accepted: 03/25/2025] [Indexed: 03/27/2025]
Abstract
G-quadruplexes (G4) are secondary structures that can form within guanine-rich DNA sequences and have cell proliferation regulatory functions. Targeting DNA G4 structures has emerged as a promising anticancer therapy, highlighting the need for new G4 ligands with reduced number of cationic groups to ensure lower toxicity. Herein, the synthesis of mono- and di-substituted 5-amino-11H-indolo[3,2-c]isoquinolines is reported. Fluorescence spectroscopy studies indicate that substitution in position 11 dictates the preference of binding to different G4. Compound 10, which features an ethylpyrrolidine side chain, demonstrates a binding preference by one order of magnitude for parallel c-MYCG4 (Kb = 107 m-1), over parallel k-RASG4 (Kb = 106 m-1), and hybrid TeloG4 and dsDNA (Kb = 105 m-1). Molecular docking studies reveal that 10 can bind not only to the flat G-quartets but also to bridge between two loops of c-MYCG4 through hydrogen bonds, which may explain its capacity to discriminate between G4. Moreover, 10 drastically reduces the cell viability of breast cancer cells at a concentration of 10 μm. Overall, herein, the discovery of a new potent and selective G4 ligand, with reduced number of side chains and with antiproliferative activity in cancer cells, is reported, which deserves to be further investigated.
Collapse